New Cell-Based therapy trial aims to tame rare nerve disease

NCT ID NCT06620809

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new treatment called NouvSoma001 for people with neuromyelitis optica spectrum disorders (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. The treatment uses tiny particles from stem cells, given via a spinal injection, to try to control the disease. The study will enroll 69 adults who recently had symptoms and will check for safety and any signs of benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430000, China

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-••••

    Contact

    Contact

    Contact